A team from UNIGE and HUG has shown that administering cell immunotherapy before surgery to remove a brain tumor is significantly more effective than administering it afterwards.

With a five-year survival rate of barely 5%, glioblastoma remains one of the deadliest brain cancers. First-line treatment consists of surgery to remove as much tumor tissue as possible.